-

Tricida to Present at the H.C. Wainwright 24th Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the H.C. Wainwright 24th Annual Global Investment Conference. Tricida will provide a company overview, business update and progress on the company’s key initiatives.

The presentation will be accessible on the Tricida website at IR.Tricida.com on Monday, September 12, 2022 at 4:30 pm PT / 1:30 pm ET. An archive of the presentation will be available for 90 days following the presentation.

About Tricida

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to slow CKD progression in patients with metabolic acidosis and CKD. Tricida is currently conducting a renal outcomes clinical trial, VALOR-CKD, to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD. Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. It is estimated to pose a health risk to approximately 4.3 million patients with CKD in the United States. There are currently no therapies approved by the FDA to slow progression of kidney disease by correcting chronic metabolic acidosis in patients with CKD.

For more information about Tricida, please visit Tricida.com.

Contacts

Jackie Cossmon
Tricida, Inc.
Senior Vice President of Investor Relations and Communications
IR@Tricida.com

Industry:

Tricida, Inc.

NASDAQ:TCDA
Details
Headquarters: South San Francisco, CA
CEO: Gerrit Klaerner
Employees: 26
Organization: PRI
Release Versions
English

Contacts

Jackie Cossmon
Tricida, Inc.
Senior Vice President of Investor Relations and Communications
IR@Tricida.com

More News From Tricida, Inc.

Tricida Announces Third Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tricida, Inc. (Nasdaq: TCDA) announced today financial results for the three and nine months ended September 30, 2022 and provided an update on key initiatives. Business Update Tricida announced in October the top-line results from its VALOR-CKD renal outcomes clinical trial, designed to evaluate veverimer’s ability to slow CKD progression in patients with metabolic acidosis and chronic kidney disease (CKD). The VALOR-CKD trial did not meet its prim...

Tricida Provides Strategic Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tricida, Inc. (NASDAQ: TCDA), announced today that the Board of Directors has authorized Tricida to initiate a review of strategic alternatives to maximize stakeholder value. To facilitate this review, Tricida has engaged Stifel and its wholly owned affiliate, Miller Buckfire, to serve as investment banking advisors and SierraConstellation Partners LLC to serve as a financial advisor. This strategic review may include consideration of the sale of th...

Tricida Reports Topline Results from the VALOR-CKD Phase 3 Trial of Veverimer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tricida, Inc. (NASDAQ: TCDA) announced today the top-line results from its VALOR-CKD renal outcomes clinical trial, designed to evaluate veverimer’s ability to slow CKD progression in patients with metabolic acidosis and chronic kidney disease (CKD). Primary Endpoint Analysis The VALOR-CKD trial did not meet its primary endpoint, which was defined as the time to the first occurrence of any event in the composite endpoint of renal death, end-stage re...
Back to Newsroom